Compare ACNT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | PYXS |
|---|---|---|
| Founded | 1945 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 71.6M |
| IPO Year | N/A | 2021 |
| Metric | ACNT | PYXS |
|---|---|---|
| Price | $16.18 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 60.8K | ★ 1.8M |
| Earning Date | 11-04-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $171,413,000.00 | $2,820,000.00 |
| Revenue This Year | $22.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $171.10 | ★ N/A |
| Revenue Growth | ★ 65.05 | N/A |
| 52 Week Low | $10.76 | $0.83 |
| 52 Week High | $16.84 | $5.55 |
| Indicator | ACNT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.02 | 23.44 |
| Support Level | $15.75 | $1.03 |
| Resistance Level | $16.68 | $4.58 |
| Average True Range (ATR) | 0.41 | 0.26 |
| MACD | -0.04 | -0.16 |
| Stochastic Oscillator | 50.00 | 4.08 |
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.